Home / Stocks / Marksans Pharma Limited
MARKSANS

Marksans Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹299.05

Change

+4.55 (1.54%)

Open

₹295.5

Prev. Close

₹294.5

Day High

₹299.9

Day Low

₹290.55

Volume Analysis

Traded

704,579

Delivered

246,126

Delivery %

34.93%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (23.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (16.2%)
  • •Strong 3-year revenue growth (16.8%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹311.8 ₹305.85 ₹302.45 ₹296.5 ₹293.1 ₹287.15 ₹283.75
Fibonacci ₹305.85 ₹302.28 ₹300.07 ₹296.5 ₹292.93 ₹290.72 ₹287.15
Camarilla ₹301.62 ₹300.76 ₹299.91 ₹296.5 ₹298.19 ₹297.34 ₹296.48

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+66.26%

1 Week

-6.55%

1 Month

+0.3%

3 Months

-6.92%

6 Months

+41.15%

1 Year

+54.89%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹123.48

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

14.87%

Net margin 16.69% × asset turnover 0.68x × equity multiplier 1.31x

Company Overview

Sector

Healthcare

Market Cap

₹13,347 Cr

P/E (TTM)

23.8

ROE

15.2%

Book Value

₹73.5

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Marksans Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (51/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (23.0%). Strong 3-year EPS growth (16.2%).

TopFund Score — Fundamentals Quality

74/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

74

Valuation

51

Cash Flow

56

Corporate Governance

73

Momentum

71

Institutional Ownership

70

Business Quality

82

Risk & Volatility

66

Liquidity

77

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Investors/Analyst meet on Q2 FY27 Financial Results

Audio recording of Q2FY27 investor call uploaded on November 05, 2026.

Newspaper Publication for Unaudited Financial Results for the quarter and half year ended September 30, 2026

Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024

Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore, with record EBITDA.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 531 586 560 591 642 682 708 620 720 754 856 841 940
Expenses + 417 453 450 462 495 543 582 520 576 594 661 628 726
Operating Profit 114 133 110 128 147 139 127 100 144 161 195 213 214
OPM % 21.0% 23.0% 20.0% 22.0% 23.0% 20.0% 18.0% 16.0% 20.0% 21.0% 23.0% 25.0% 23.0%
Other Income + 19 5 17 15 0 28 15 6 22 20 35 25 18
Interest 2 3 5 3 3 3 3 6 6 6 6 7 7
Depreciation 18 22 21 20 20 21 23 23 27 24 24 25 32
Profit before tax 114 113 100 120 125 143 116 77 133 151 200 207 194
Tax % 26.0% 26.0% 23.0% 26.0% 22.0% 27.0% 22.0% 24.0% 26.0% 25.0% 25.0% 23.0% 26.0%
Net Profit + 84 83 78 89 98 105 91 58 99 114 149 159 144
EPS in Rs 2 2 2 2 2 2 2 1 2 3 3 3 3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 17 22 15 18 21 16 27 5 12 11 21 36 30

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 797 893 767 913 1,000 1,134 1,376 1,491 1,852 2,177 2,623 2,951 3,392
Expenses + 612 757 722 834 868 942 1,037 1,232 1,513 1,719 2,090 2,350 2,608
Operating Profit 185 136 45 78 132 192 340 259 340 459 533 601 784
OPM % 23.0% 15.0% 6.0% 9.0% 13.0% 17.0% 25.0% 17.0% 18.0% 21.0% 20.0% 20.0% 23.0%
Other Income + 3 9 7 8 5 0 7 42 59 50 66 82 99
Interest 16 10 7 10 10 9 8 8 9 11 12 24 26
Depreciation 16 28 30 27 23 27 36 45 52 74 83 99 106
Profit before tax 156 107 15 50 104 157 302 248 338 424 504 561 751
Tax % 28.0% 23.0% 24.0% 28.0% 23.0% 23.0% 21.0% 25.0% 21.0% 26.0% 24.0% 25.0% —
Net Profit + 112 83 11 36 80 121 239 187 265 315 383 420 566
EPS in Rs 3 2 0 1 2 3 6 5 6 7 8 9 12
Dividend Payout % 4.0% 21.0% 23.0% 6.0% 3.0% 3.0% 4.0% 6.0% 9.0% 9.0% 10.0% 10.0% —
Sales growth 26 12 -14 19 10 13 21 8 24 18 20 13 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 326 401 392 430 502 595 846 1,161 1,700 2,020 2,422 2,978 3,287
Borrowings + 101 100 110 118 100 30 34 111 123 244 322 343 465
Other Liabilities + 207 180 209 142 160 236 307 323 322 372 451 489 563
Total Liabilities 676 722 752 731 802 902 1,228 1,636 2,190 2,681 3,240 3,856 4,360
Fixed Assets + 166 270 267 279 270 303 309 428 486 776 982 1,044 1,313
CWIP 0 0 0 0 0 0 12 3 10 9 27 59 5
Investments 0 0 0 0 0 0 0 0 1 27 1 0 62
Other Assets + 510 452 484 451 533 599 907 1,205 1,694 1,869 2,230 2,753 2,979
Total Assets 676 722 752 731 802 902 1,228 1,636 2,190 2,681 3,240 3,856 4,360
Equity Capital 41 41 41 41 41 41 41 41 45 45 45 45 45

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 155 31 14 50 27 233 179 99 237 230 207 458
Cash from Investing Activity + -33 -123 -21 -39 -13 -60 -45 -84 -259 -141 -49 -249
Cash from Financing Activity + 17 -58 -3 3 -21 -114 -15 80 198 -69 -65 -71
Net Cash Flow 138 -150 -10 15 -7 60 118 94 176 21 93 138
Free Cash Flow 118 -101 -14 11 14 174 133 53 184 22 35 329
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 108 43 31 73 41 134 67 66 88 77 62 99

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 43.85% → 43.87%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 35.81% 35.4% 33.77% 30.7% 29.88% 29.37% 30.74% 33.93% 42.08% 32.78% 32.46% 31.53%
Promoters 43.85% 43.85% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87% 43.87%
FII 15.55% 15.57% 18.59% 21.31% 21.95% 22.19% 19.89% 16.92% 8.13% 16.76% 17.47% 19.06%
DII 4.76% 5.17% 3.75% 4.1% 4.3% 4.55% 5.5% 5.28% 5.91% 6.57% 6.19% 5.54%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Marksans Pharma Limited (this stock) 13,347 23.8 4.0 15.2%
Sudeep Pharma Limited 13,545 71.9 14.14 25.2%
Corona Remedies Limited 14,010 63.6 17.34 29.5%
Rainbow Childrens Med Ltd 12,607 43.0 7.34 16.7%
Vijaya Diagnostic Cen Ltd 14,524 71.3 13.69 18.9%
Concord Biotech Limited 12,146 42.6 5.86 12.9%
Jubilant Pharmova Ltd 14,883 50.4 2.08 6.53%

Which Mutual Funds Hold Marksans Pharma Limited?

Frequently Asked Questions about Marksans Pharma Limited

Community Sentiment

What are other investors saying about Marksans Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.